Lacimto: A Comprehensive Guide to Its Uses and Applications
Having the appropriate solutions is very important when dealing with any kidney-related conditions. That is why Lacimto comes in handy. This manual reviews the product’s functions in the correction of elevated phosphate levels for patients on dialysis. It is one of the products designed to enhance the healthcare industry, offered by Torso Lifesciences which is able to address the needs for nephrology products in the market.

Understanding Lacimto: What Is It?
Lacimto reduces phosphate blood levels in dialysis patients suffering from renal failure. After a certain stage of renal failure, the kidneys become ineffective at removing excess phosphate from the body. Each Lacimto tablet contains Calcium Acetate (667 mg per tablet) as a phosphate binder. This phosphate binds with the foodstuff and is eventually expelled. Reduction of phosphate levels helps strengthen bones, decrease accumulation of minerals so as to lower heart diseases and strokes.

Healthcare Applications of Lacimto
The major use of this product highly fall into the category of healthcare especially hyperphosphate, which is the increased concentration of Phosphate in the blood. And this is more critical in patients who are in dialysis since such form of therapy is not effective in addressing phosphate problems. Lacimto works to control these levels, protecting the patients from effects such as bone disease, and cardiovascular complications.

How does Lacimto work?
When Lacimto is taken with meals, it works the best. It’s active component, calcium acetate, gets combined with dietary phosphate in the intestines. As a result, insoluble calcium phosphate is formed further, which gets excreted in the stool. This makes Lacimto dependable in maintaining the phosphate concentration in patients on dialysis.

Dosage and Administration Guidelines
In the management of hyperphosphatemia using Lacimto, the dose is very crucial. A starting dose of 1334 mg (2 tablets) is to be given three times a day after each meal. This can be done progressively to suit the phosphate scale of the patient. It is extremely necessary to consult a physician before finding ways to change the dose.

Conclusion
Dialysis patients who use Lacimto achieve satisfactory target phosphate levels against heath needs. All patients suffering from kidney diseases, or other people in contact with such people, may see that discussing Lacimto with a healthcare provider is a way of health improvement.

For more information about Lacimto and other products of nephrology, contact Torso Lifesciences. Together, let us work towards a healthy globe.

https://www.torso.co.in/blogs-....detail/lacimto-a-com

OTF-Soft | Torso Life Sciences

OTF-SOFT, Omega-3 Marine Triglycerides Capsules are polyunsaturated fatty acids (PUFAs). involved in human physiology includes Eicosapentaenoic acid (EPA), and Docosahexaenoic acid (DHA). Omega-3 fatty acids play a critical role in metabolism and cellular function, possess potent antiarrhythmic effects, form the structures of the cell membranes and also serve as energy source. They form eicosanoids which are important signaling molecules with wide-ranging functions in the body cardiovascular, pulmonary, immune and endocrine systems. DHA tends to exist in high concentrations in the retina and brain.

Composition
Omega 3 Marine Triglycerides — EPA 180 mg, DHA 120 mg

Mode of Action
Omega-3 fatty acids mediate anti-inflammatory effects and increased levels of EPA or DHA has shown to decrease the levels of PGE2 and 4 series-LT. Eicosapentaenoic acids compete with constitutive levels of arachidonic acid in cell membranes for the same desaturation enzymes and produce 3-series prostaglandins and thromboxanes, and 5-series leukotrienes which have low pro-inflammatory potential. The alteration in leukotriene biosynthesis due to higher concentration of omega-3 fatty acids compared to arachidonic acid underlies the anti-inflammatory effects. EPA and DHA also give rise to resolvins and related lipid signaling molecules such as protectins via cyclooxygenase and lipoxygenase pathways, which have anti-inflammatory effects. They inhibit transendothelial migration of neutrophils and inhibit TNF and IL-1β production.

Indications
Omega-3 fatty acids reduce inflammation, proteinuria and slow the progression of kidney disease. This can further help prevent further decline of kidney function in patients with CKD, and reduce risk of developing end-stage renal disease.

Dosage
1–2 Capsules / Day.

This information is for the registered medical practitioners only. Consult your medical practitioner before consuming the products.

Torso Lifesciences Pvt. Ltd.
29, Second Floor, Swastik House, Nr. Income Tax Crossing, Stadium Road, Navrangpura, Ahmedabad — 380009

Website: www.torso.co.in
Phone: 079–48488946
Email: info@torso.co.in

https://www.torso.co.in/product-detail/otf-soft

Lacimto is used to prevent high blood phosphate levels in patients who are on dialysis due to severe kidney disease. Dialysis removes some phosphate from your blood, but it is difficult to remove enough to keep your phosphate levels balanced. Decreasing blood phosphate levels can help keep your bones strong, prevent unsafe buildup of minerals in your body, and possibly decrease the risk of heart disease and strokes that can result from high phosphate levels. Calcium acetate is a natural mineral that works by holding onto phosphate from the diet so that it can pass out of your body.

Composition
Calcium Acetate Tablets USP 667mg

Mode of Action
Dialysis patients absorb 40% to 80% of dietary phosphorus. Therefore, the fraction of dietary phosphate absorbed from the diet needs to be reduced by using phosphate binders in most renal failure patients on maintenance dialysis. Calcium acetate when taken with meals combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders. Calcium acetate is highly soluble at neutral pH, making the calcium readily available for binding to phosphate in the proximal small intestine.

Indications
Calcium acetate is used to treat hyperphosphatemia (too much phosphate in the blood) in patients with kidney disease.

Dosage
1. Usual Adult Dose for Hyperphosphatemia, 2. Initial dose: 1334 mg (2 tablets/capsules), orally, with each meal, 3. Maintenance dose: 2001 to 2668 mg (3 to 4 tablets/capsules) with each meal, 4. Titrate dose every 2 to 3 weeks until an acceptable serum phosphorous level is reached.

This information is for the registered medical practitioners only. Consult your medical practitioner before consuming the products.

https://www.torso.co.in/product-detail/Lacimto